iRadimed (NASDAQ:IRMD) Announces Earnings Results

iRadimed (NASDAQ:IRMD) released its quarterly earnings data on Friday. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.55, FiscalAI reports. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.

Here are the key takeaways from iRadimed’s conference call:

• Record third-quarter results included revenue of $24.2 million, up 14% year over year and 18% sequentially, while GAAP EPS rose to $0.51 from $0.43 a year ago.
• The 3870 MR IV pump launch is gaining traction, with more than 300 systems shipped in Q3, record pump and monitor bookings, and a growing backlog. Management estimates an opportunity of more than 10,000 replacement channels, with the new pump carrying an approximately 23%-25% higher ASP than the older model.
• The company reduced its 2026 revenue outlook to $91.7 million-$93.2 million from $91 million-$96 million and lowered its GAAP EPS range to $1.90-$1.94 from $1.90-$2.05, citing the need to moderate production ramping to protect quality.
• Manufacturing efficiencies lifted gross margin to 76% sequentially, and management expects further improvement in Q4 and potentially a return to 77%-78% or higher in 2027. Management also projected double-digit, potentially upper-teens, revenue growth in 2027 and ended the quarter with $63.3 million in cash while declaring a $0.20 quarterly dividend.

iRadimed Stock Down 10.5%

Shares of IRMD traded down $8.96 during trading hours on Friday, reaching $76.78. The stock had a trading volume of 140,509 shares, compared to its average volume of 111,432. The company has a market cap of $981.72 million, a P/E ratio of 42.90 and a beta of 0.91. iRadimed has a 52 week low of $76.38 and a 52 week high of $107.90. The firm has a 50-day moving average of $85.86 and a 200 day moving average of $92.79.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on IRMD shares. Weiss Ratings upgraded shares of iRadimed from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, October 16th. Wall Street Zen lowered iRadimed from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Needham & Company LLC began coverage on shares of iRadimed in a research note on Tuesday, September 22nd. They issued a “hold” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, iRadimed currently has an average rating of “Moderate Buy” and an average target price of $120.00.

Insider Transactions at iRadimed

In other iRadimed news, Director Monty K. Allen sold 1,419 shares of the stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $86.41, for a total value of $122,615.79. Following the completion of the sale, the director directly owned 19,581 shares in the company, valued at $1,691,994.21. This represents a 6.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 34.60% of the company’s stock.

About iRadimed

iRadimed Corporation (NASDAQ: IRMD) develops, manufactures and sells medical devices designed for use during magnetic resonance imaging (MRI) procedures. The company focuses on solutions that allow clinicians to deliver intravenous medications and monitor patients safely while they are in or near an MRI scanner.

Its principal products include the MRidium MRI-compatible infusion pump systems, which are designed to administer intravenous fluids and medications without interfering with MRI operations.